PIWA
CUE icon

Prevail Innovative Wealth Advisors’s Cue Biopharma CUE Stock Holding History

Prevail Innovative Wealth Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-633
Closed -$4.37K – 214
2026
Q1 		$4.37K Hold
633
– – ﹤0.01% 178
2025
Q4 		$5.8K Hold
633
– – ﹤0.01% 188
2025
Q3 		$13.6K Hold
633
– – ﹤0.01% 201
2025
Q2 		$13K Buy
+633
New +$13.5K ﹤0.01% 193

Other funds holding CUE

RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prevail Innovative Wealth Advisors's CUE Position: Q2 2026 in Review

Prevail Innovative Wealth Advisors sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 633 shares — an estimated $4.37K sold.

Prevail Innovative Wealth Advisors first reported a position in CUE in Q2 2025 and held it in 4 quarters. The position peaked at $13.6K in Q3 2025. 8 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Prevail Innovative Wealth Advisors reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
  • Prevail Innovative Wealth Advisors sold 633 Cue Biopharma shares in Q2 2026, an estimated $4.37K.
  • Prevail Innovative Wealth Advisors first reported a position in Cue Biopharma in Q2 2025 and held it in 4 quarters.
  • Prevail Innovative Wealth Advisors's Cue Biopharma position peaked at $13.6K in Q3 2025.
  • 8 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Prevail Innovative Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.